PMID- 18249584 OWN - NLM STAT- MEDLINE DCOM- 20080529 LR - 20220316 IS - 1471-4906 (Print) IS - 1471-4906 (Linking) VI - 29 IP - 3 DP - 2008 Mar TI - HLA-G: from biology to clinical benefits. PG - 125-32 LID - 10.1016/j.it.2007.11.005 [doi] AB - The relevance of the nonclassical human leukocyte antigen (HLA) class I molecule HLA-G in human physiological and pathological contexts has been the center of intense investigation. In light of the recent advances, we report here the clinical implications of HLA-G as a tolerogenic molecule promoting uterine implantation of the embryo or acceptance of solid allografts while allowing the evasion of tumors or viruses from the immune response. These recent findings are important in terms of clinical benefits at both diagnostic and therapeutic levels. FAU - Carosella, Edgardo D AU - Carosella ED AD - Institut Universitaire d'Hematologie, Service de Recherches en Hemato-Immunologie, Hopital Saint-Louis, IUH, 1 75010 Paris, France. FAU - Moreau, Philippe AU - Moreau P FAU - Lemaoult, Joel AU - Lemaoult J FAU - Rouas-Freiss, Nathalie AU - Rouas-Freiss N LA - eng PT - Journal Article PT - Review DEP - 20080204 PL - England TA - Trends Immunol JT - Trends in immunology JID - 100966032 RN - 0 (HLA Antigens) RN - 0 (HLA-G Antigens) RN - 0 (Histocompatibility Antigens Class I) SB - IM MH - Animals MH - Embryo Implantation/immunology MH - HLA Antigens/*physiology/*therapeutic use MH - HLA-G Antigens MH - Histocompatibility Antigens Class I/*physiology/*therapeutic use MH - Humans MH - Transplantation Tolerance/immunology MH - Tumor Escape/immunology RF - 77 EDAT- 2008/02/06 09:00 MHDA- 2008/05/30 09:00 CRDT- 2008/02/06 09:00 PHST- 2007/10/19 00:00 [received] PHST- 2007/11/20 00:00 [revised] PHST- 2007/11/27 00:00 [accepted] PHST- 2008/02/06 09:00 [pubmed] PHST- 2008/05/30 09:00 [medline] PHST- 2008/02/06 09:00 [entrez] AID - S1471-4906(08)00005-7 [pii] AID - 10.1016/j.it.2007.11.005 [doi] PST - ppublish SO - Trends Immunol. 2008 Mar;29(3):125-32. doi: 10.1016/j.it.2007.11.005. Epub 2008 Feb 4.